Nuclear auto-antibodies: a useful tool for the diagnosis, the classification and the prognosis of systemic sclerosis

被引:10
作者
Hachulla, E [1 ]
Dubucquoi, S
机构
[1] CHRU, Hop Claude Huriez, Serv Med Interne, F-59037 Lille, France
[2] Fac Med Lille, Immunol Lab, F-59045 Lille, France
来源
REVUE DE MEDECINE INTERNE | 2004年 / 25卷 / 06期
关键词
systemic sclerosis; nuclear antibodies; diagnosis; prognosis;
D O I
10.1016/j.revmed.2003.11.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose. - Systemic sclerosis (SSc) like other connective tissue diseases is characterized by the occurrence of antinuclear auto-antibodies (ANA). We reviewed the diagnostic value and prognostic value of ANA in SSc. Current knowledge and key points. - LeRoy proposed new criteria of limited forms of SSc which take into account the immunological profile of the patients. Anticentromere, antitopoisomerase I, antifibrillarin, anti-PM-Scl, antifibrillin or anti-RNA-polymerase I or III are considered as specific anti -autobodies. Whereas anticentromere antibodies are more associated with limited SSc and antitopoisomerase I with diffuse SSc, other auto-antibodies were associated with other organ involvement: anti-RNA-polymerase I or III and renal crisis, anti-U1-RNP and pulmonary hypertension and pulmonary fibrosis, etc. Patient with persistent antitopoisomerase I antibodies have a poor survival, those with antitopoisomerase antibodies that disappear with time have a better prognosis. Future prospects and projects. - A better identification of the patients with SSc, an individual biological profile and organ involvement may help better management of the disease and better access to clinical trials. The development of new immunological tests and their clinical application should help us in that way. (C) 2003 Elsevier SAS. Tous droits reserves.
引用
收藏
页码:442 / 447
页数:6
相关论文
共 37 条
  • [1] Clinical, serological and genetic study in patients with CREST syndrome
    Akiyama, Y
    Tanaka, M
    Takeishi, M
    Adachi, D
    Mimori, A
    Suzuki, T
    [J]. INTERNAL MEDICINE, 2000, 39 (06) : 451 - 456
  • [2] PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA)
    不详
    [J]. ARTHRITIS AND RHEUMATISM, 1980, 23 (05): : 581 - 590
  • [3] Arnett FC, 1999, ARTHRITIS RHEUM-US, V42, P2656, DOI 10.1002/1529-0131(199912)42:12<2656::AID-ANR22>3.0.CO
  • [4] 2-N
  • [5] Bardoni A, 2003, CLIN EXP RHEUMATOL, V21, P301
  • [6] Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis
    Dick, T
    Mierau, R
    Bartz-Bazzanella, P
    Alavi, M
    Stoyanova-Scholz, M
    Kindler, J
    Genth, E
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (02) : 121 - 127
  • [7] Immunological diagnostic of scleroderma
    Fabien, N
    Rousset, H
    [J]. PATHOLOGIE BIOLOGIE, 2002, 50 (04): : 243 - 255
  • [8] FAUTREL B, 2000, MALADIES SYNDROMES S, P469
  • [9] AUTOANTIBODIES TO MITOCHONDRIA IN SYSTEMIC-SCLEROSIS - FREQUENCY AND CHARACTERIZATION USING RECOMBINANT CLONED AUTO-ANTIGEN
    FREGEAU, DR
    LEUNG, PSC
    COPPEL, RL
    MCNEILAGE, LJ
    MEDSGER, TA
    GERSHWIN, ME
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 386 - 392
  • [10] Disease severity as a predictor of outcome in scleroderma
    Gelber, AC
    Wigley, FM
    [J]. LANCET, 2002, 359 (9303) : 277 - 279